I am particularly interested in earnings at one of them,
American International Group
(AIG), as I finish reading a captivating book titled "The AIG Story" by
former CEO Hank Greenberg and Lawrence Cunningham. If you think you know AIG, you don't know the half of it without knowing its history. Greenberg and Cunningham splendidly layout the trials, setbacks and successes of this enormous insurance giant. It's a fun, engrossing read, and if you're an AIG investor you're crazy not to put your hands on a copy.
PFE data by
Pfizer (PFE) is an attractive leader in the pharmaceutical space. Pfizer engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide.
52-Week Range: $21.40 to $31.15Price To Book: 2.7 I covered Pfizer in several articles, including "Rising Dividend Stocks That Don't Care About the Fiscal Cliff" before the beginning of 2013. Since my bullish article, Pfizer's shares increased 20% even after dipping lower Friday as a result of Europe rejecting an arthritis medication. It appears the drop in price was another buying opportunity.
Investors are anticipating little to no profit growth in when it reports. Analysts are forecasting per share results below the equivalent quarter last year. The earnings release is planned before the market opens on Tuesday. The average estimate is currently 56 cents a share, slipping 2 cents (3.4%) from 58 cents during the corresponding quarter last year. Analysts' estimates this quarter range from 52 cents to a high of 63 cents per share. Analysts as a whole like this company. Currently, Pfizer has 16 buy recommendations out of 21 analysts covering the company, along with four holds and one sell rating. Shares have tremendously appreciated, gaining 32% in the last year, and the average analyst target price for Pfizer is $30.99. Don't be surprised if you begin to see analysts raising their targets above $31 if the earnings report is solid. The company currently pays a monster 96 cents per share in dividends for a yield of 3.2%. The substantial yield is the primary reason I have steadfastly remained bullish through 2012, and why 2013 has the essentials for a great year to own Pfizer. There is almost no desire from short sellers to position against this stock. Short interest doesn't even move the needle at only 0.8% of the float. PFE Revenue Quarterly data by YCharts
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV